COMMUNIQUÉS West-GlobeNewswire

-
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
10/06/2024 -
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
10/06/2024 -
Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024
10/06/2024 -
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
10/06/2024 -
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
08/06/2024 -
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
08/06/2024 -
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
08/06/2024 -
Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
07/06/2024 -
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07/06/2024 -
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
07/06/2024 -
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
07/06/2024 -
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
07/06/2024 -
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/06/2024 -
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/06/2024 -
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/06/2024 -
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/06/2024 -
StateHouse Sets Date to Report Fourth Quarter and Year-End 2023 Financial Results and First Quarter 2024 Financial Results
07/06/2024 -
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
07/06/2024 -
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
07/06/2024
Pages